Drug intelligence / Profile preview

GDT-201

Development stage: Unknown
Lead developer: Century Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

GDT-201 is a preclinical cell therapy developed by Gadeta B.V., now a wholly-owned subsidiary of Clade Therapeutics. It utilizes a proprietary gamma/delta (g/d) T-cell receptor (TCR) universal targeting platform to develop engineerable, off-the-shelf, scalable stem-cell-based medicines for cancer. The drug is specifically designed to target solid tumors, including colorectal cancer, by recognizing tumor-specific antigens. GDT-201 incorporates a proprietary bi-directional co-stimulatory mechanism (MiDis) to enhance its cytotoxic activity within the suppressive tumor microenvironment. Preclinical studies have demonstrated its ability to eradicate colorectal cancer in in vivo models.

Beyond the preview

Go deeper on GDT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDT-201.

Explore the full profile